search
Back to results

Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

Primary Purpose

Acute Respiratory Distress Syndrome (ARDS)

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Inhaled Carbon Monoxide at 100ppm (4 participants)
Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)
Inhaled Carbon Monoxide at 200ppm (4 participants)
Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Respiratory Distress Syndrome (ARDS)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with sepsis are defined as those with suspected or documented infection:

    Suspected or proven infection: Sites of infection include thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system

    All eligible patients meet the new definition of sepsis (suspected or proven infection and a SOFA ≥ 2) as PaO2/FiO2 ratio < 300 = 2 SOFA points.

  2. ARDS is defined when all four of the following criteria are met:

    • A PaO2/FiO2 ratio ≤ 300 with at least 5 cm H2O positive end-expiratory airway pressure (PEEP)
    • Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph
    • A need for positive pressure ventilation by an endotracheal or tracheal tube
    • No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.
  3. ARDS onset is defined as the time the last of criteria 1-4 are met. ARDS must persist through the enrollment time window of 120 hours.
  4. Infiltrates considered "consistent with pulmonary edema" include any infiltrates not fully explained by mass, atelectasis, or effusion or opacities known to be chronic (greater than 1 week). Vascular redistribution, indistinct vessels, and indistinct heart borders alone are not considered "consistent with pulmonary edema" and thus would not count as qualifying opacities for this study.

Exclusion Criteria:

  1. Age less than 18 years
  2. Greater than 120 hours since ARDS onset
  3. Pregnant or breast-feeding
  4. Prisoner
  5. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)
  6. No consent/inability to obtain consent
  7. Physician refusal to allow enrollment in the trial
  8. Moribund patient not expected to survive 24 hours
  9. No arterial line/no intent to place an arterial line
  10. No intent/unwillingness to follow lung protective ventilation strategy
  11. Severe hypoxemia defined as oxygenation saturation (SpO2) <95 or PaO2 <80 on FiO2 ≥0.8
  12. Hemoglobin < 7.5 g/dl or hemoglobin < 8 g/dl and actively bleeding
  13. Subjects who are Jehovah's Witnesses or are otherwise unable or unwilling to receive blood transfusions during hospitalization
  14. Acute myocardial infarction (MI) or acute coronary syndrome (ACS) within the last 90 days
  15. Coronary artery bypass graft (CABG) surgery within 30 days
  16. Angina pectoris or use of nitrates with activities of daily living
  17. Cardiopulmonary disease classified as New York Heart Association (NYHA) class IV
  18. Stroke (ischemic or hemorrhagic) within the prior 3 months
  19. Diffuse alveolar hemorrhage from vasculitis
  20. Use of high frequency ventilation
  21. Participation in other interventional studies involving investigational agents
  22. Burns > 40% total body surface area
  23. Use of inhaled pulmonary vasodilator therapy (eg. NO or prostaglandins)

Sites / Locations

  • Massachusetts General Hospital
  • Brigham and Women's Hospital
  • Weill Cornell Medical College/NewYork-Presbyterian
  • Duke Univesity Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Cohort 1

Cohort 1 (placebo)

Cohort 2

Cohort 2 (Placebo)

Arm Description

Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days

Inhaled Medical Air for up to 90 minutes daily for 5 days

Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days

Inhaled Medical Air for up to 90 minutes daily for 5 days

Outcomes

Primary Outcome Measures

Number of administration associated adverse events.
Acute myocardial infarction (MI) within 48 hours of study drug administration Acute cerebrovascular accident (CVA) within 48 hours of study drug administration New onset atrial or ventricular arrhythmia requiring direct current (DC) cardioversion within 48 hours of study drug administration Increased oxygenation requirements defined as: an increase in fraction of inspired oxygen (FiO2) of greater than or equal to 0.2 AND increase in PEEP greater than or equal to 5 cm of water (H2O) within 6 hours of study drug administration Increase in any protocol-specified measurement of carboxyhemoglobin (COHb) greater than or equal to 10% Increase in lactate by greater than or equal to 2 mmol/L within 6 hours of study drug administration
Incidence of serious adverse events (SAEs).
An SAE is any event that is fatal or immediately life threatening, is permanently disabling, or severely incapacitating, or requires or prolongs inpatient hospitalization. Important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed above.

Secondary Outcome Measures

Comparison between the calculated carboxyhemoglobin (COHb) level at 90 minutes using the Coburn-Forster-Kane (CFK) equation and measured COHb level at 90 minutes
The Coburn-Forster-Kane (CFK) equation will be used to calculate the estimated COHb level at 90 minutes for Cohorts 1 and 2.
Mean daily Sequential Organ Failure Assessment (SOFA) score
Organ failure will be assessed using the SOFA score. SOFA scores will be assessed daily on days 1-5, and day 7, as the SOFA score has been shown to be a reliable prognostic indicator of outcomes in critically ill patients.
Partial pressure of arterial oxygen (PaO2)/FiO2 ratio
PaO2/FiO2 will be measured daily on days 1-5 if a subject remains mechanically ventilated.
Oxygenation index (OI)
The OI will be measured daily on days 1-5 if a subject remains mechanically ventilated.
Lung injury score (LIS)
The LIS is a composite 4-point scoring system including the PaO2/FiO2, PEEP, quasi-static respiratory compliance, and the extent of infiltrates on the chest X-ray. Previous randomized clinical trials in ARDS have shown that a decreased LIS correlates with improvement in lung physiology as well as important clinical outcomes including mortality and ventilator-free days (VFDs).
Vasopressor-free days
Ventilator-free days will be assessed on day 28.
Ventilator-free days (VFDs)
Ventilator-free days to day 28 are defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject returns to assisted breathing and subsequently achieves unassisted breathing to day 28, VFDs will be counted from the end of the last period of assisted breathing to day 28.
ICU-free days
ICU-free days will be assessed on day 28.
Hospital-free days
Hospital-free days will be assessed on day 60.

Full Information

First Posted
March 17, 2015
Last Updated
October 15, 2019
Sponsor
Brigham and Women's Hospital
Collaborators
Weill Medical College of Cornell University, Massachusetts General Hospital, Duke University
search

1. Study Identification

Unique Protocol Identification Number
NCT02425579
Brief Title
Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)
Official Title
A Phase I Trial of Inhaled Carbon Monoxide for the Treatment of Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
August 2019 (Actual)
Study Completion Date
August 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
Collaborators
Weill Medical College of Cornell University, Massachusetts General Hospital, Duke University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the safety of inhaled carbon monoxide (iCO) in intubated patients with sepsis-induced ARDS.
Detailed Description
The acute respiratory distress syndrome (ARDS) is a syndrome of severe acute lung inflammation and hypoxemic respiratory failure with an incidence of 180,000 cases annually in the U.S.Despite decades of research and recent advances in lung protective ventilator strategies, morbidity and mortality remain unacceptably high. Furthermore, no specific effective pharmacologic therapies currently exist. The lack of specific effective therapies for sepsis-related ARDS indicates a need for new treatments that target novel pathways. Carbon monoxide (CO) represents a novel therapeutic modality in ARDS based on data obtained in experimental models of ARDS and sepsis over the past decade. CO has been shown to be protective in experimental models of Acute Lung Injury (ALI), including hyperoxia and endotoxin exposure, bleomycin, ischemia/reperfusion, and ventilator-induced lung injury (VILI). At low doses, CO has been shown to confer tissue protective effects in these ALI models. In addition, CO has been shown to decrease inflammation, enhance phagocytosis, and improve mortality in models of sepsis including endotoxemia, hemorrhagic shock, and cecal ligation and puncture (CLP). CO has also been shown to have beneficial therapeutic effects in pre-clinical models of disease including pulmonary hypertension, vascular injury, and transplantation. Furthermore, multiple human studies have demonstrated that experimental administration of several different concentrations of CO is well tolerated and that low dose inhaled CO can be safely administered to subjects in a controlled research environment. The purpose of this study is to assess the safety of inhaled CO therapy in mechanically ventilated patients with sepsis-induced ARDS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Respiratory Distress Syndrome (ARDS)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days
Arm Title
Cohort 1 (placebo)
Arm Type
Placebo Comparator
Arm Description
Inhaled Medical Air for up to 90 minutes daily for 5 days
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days
Arm Title
Cohort 2 (Placebo)
Arm Type
Placebo Comparator
Arm Description
Inhaled Medical Air for up to 90 minutes daily for 5 days
Intervention Type
Drug
Intervention Name(s)
Inhaled Carbon Monoxide at 100ppm (4 participants)
Other Intervention Name(s)
iCO
Intervention Description
Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
Intervention Type
Drug
Intervention Name(s)
Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)
Other Intervention Name(s)
Inhaled Medical Air
Intervention Description
Inhaled Medical Air for up to 90 minutes daily for 5 days
Intervention Type
Drug
Intervention Name(s)
Inhaled Carbon Monoxide at 200ppm (4 participants)
Other Intervention Name(s)
iCO
Intervention Description
Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
Intervention Type
Drug
Intervention Name(s)
Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)
Other Intervention Name(s)
Inhaled Medical Air
Intervention Description
Inhaled Medical Air for up to 90 minutes daily for 5 days
Primary Outcome Measure Information:
Title
Number of administration associated adverse events.
Description
Acute myocardial infarction (MI) within 48 hours of study drug administration Acute cerebrovascular accident (CVA) within 48 hours of study drug administration New onset atrial or ventricular arrhythmia requiring direct current (DC) cardioversion within 48 hours of study drug administration Increased oxygenation requirements defined as: an increase in fraction of inspired oxygen (FiO2) of greater than or equal to 0.2 AND increase in PEEP greater than or equal to 5 cm of water (H2O) within 6 hours of study drug administration Increase in any protocol-specified measurement of carboxyhemoglobin (COHb) greater than or equal to 10% Increase in lactate by greater than or equal to 2 mmol/L within 6 hours of study drug administration
Time Frame
60 Days if remains in the ICU
Title
Incidence of serious adverse events (SAEs).
Description
An SAE is any event that is fatal or immediately life threatening, is permanently disabling, or severely incapacitating, or requires or prolongs inpatient hospitalization. Important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
Time Frame
60 Days if remains in the ICU
Secondary Outcome Measure Information:
Title
Comparison between the calculated carboxyhemoglobin (COHb) level at 90 minutes using the Coburn-Forster-Kane (CFK) equation and measured COHb level at 90 minutes
Description
The Coburn-Forster-Kane (CFK) equation will be used to calculate the estimated COHb level at 90 minutes for Cohorts 1 and 2.
Time Frame
5 days
Title
Mean daily Sequential Organ Failure Assessment (SOFA) score
Description
Organ failure will be assessed using the SOFA score. SOFA scores will be assessed daily on days 1-5, and day 7, as the SOFA score has been shown to be a reliable prognostic indicator of outcomes in critically ill patients.
Time Frame
7 days
Title
Partial pressure of arterial oxygen (PaO2)/FiO2 ratio
Description
PaO2/FiO2 will be measured daily on days 1-5 if a subject remains mechanically ventilated.
Time Frame
5 days
Title
Oxygenation index (OI)
Description
The OI will be measured daily on days 1-5 if a subject remains mechanically ventilated.
Time Frame
5 days
Title
Lung injury score (LIS)
Description
The LIS is a composite 4-point scoring system including the PaO2/FiO2, PEEP, quasi-static respiratory compliance, and the extent of infiltrates on the chest X-ray. Previous randomized clinical trials in ARDS have shown that a decreased LIS correlates with improvement in lung physiology as well as important clinical outcomes including mortality and ventilator-free days (VFDs).
Time Frame
7 Days
Title
Vasopressor-free days
Description
Ventilator-free days will be assessed on day 28.
Time Frame
28 days
Title
Ventilator-free days (VFDs)
Description
Ventilator-free days to day 28 are defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject returns to assisted breathing and subsequently achieves unassisted breathing to day 28, VFDs will be counted from the end of the last period of assisted breathing to day 28.
Time Frame
28 days
Title
ICU-free days
Description
ICU-free days will be assessed on day 28.
Time Frame
28 days
Title
Hospital-free days
Description
Hospital-free days will be assessed on day 60.
Time Frame
60 days
Other Pre-specified Outcome Measures:
Title
Plasma biomarkers of inflammation, lung epithelial injury,endothelial injury, markers of change in other end-organ function
Description
Specific Biomarkers: Plasma biomarkers of inflammation (IL-6, IL-8, IL-10, IL-1 receptor antagonist (IL-1Ra), IL-18, IL-1β, and circulating mitochondrial DNA), lung epithelial injury (RAGE), endothelial injury (vWF, Ang-2), markers of change in other end-organ function (e.g., creatinine, liver function tests, lactate)
Time Frame
5 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with sepsis are defined as those with suspected or documented infection: Suspected or proven infection: Sites of infection include thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system All eligible patients meet the new definition of sepsis (suspected or proven infection and a SOFA ≥ 2) as PaO2/FiO2 ratio < 300 = 2 SOFA points. ARDS is defined when all four of the following criteria are met: A PaO2/FiO2 ratio ≤ 300 with at least 5 cm H2O positive end-expiratory airway pressure (PEEP) Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph A need for positive pressure ventilation by an endotracheal or tracheal tube No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates. ARDS onset is defined as the time the last of criteria 1-4 are met. ARDS must persist through the enrollment time window of 120 hours. Infiltrates considered "consistent with pulmonary edema" include any infiltrates not fully explained by mass, atelectasis, or effusion or opacities known to be chronic (greater than 1 week). Vascular redistribution, indistinct vessels, and indistinct heart borders alone are not considered "consistent with pulmonary edema" and thus would not count as qualifying opacities for this study. Exclusion Criteria: Age less than 18 years Greater than 120 hours since ARDS onset Pregnant or breast-feeding Prisoner Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) No consent/inability to obtain consent Physician refusal to allow enrollment in the trial Moribund patient not expected to survive 24 hours No arterial line/no intent to place an arterial line No intent/unwillingness to follow lung protective ventilation strategy Severe hypoxemia defined as oxygenation saturation (SpO2) <95 or PaO2 <80 on FiO2 ≥0.8 Hemoglobin < 7.5 g/dl or hemoglobin < 8 g/dl and actively bleeding Subjects who are Jehovah's Witnesses or are otherwise unable or unwilling to receive blood transfusions during hospitalization Acute myocardial infarction (MI) or acute coronary syndrome (ACS) within the last 90 days Coronary artery bypass graft (CABG) surgery within 30 days Angina pectoris or use of nitrates with activities of daily living Cardiopulmonary disease classified as New York Heart Association (NYHA) class IV Stroke (ischemic or hemorrhagic) within the prior 3 months Diffuse alveolar hemorrhage from vasculitis Use of high frequency ventilation Participation in other interventional studies involving investigational agents Burns > 40% total body surface area Use of inhaled pulmonary vasodilator therapy (eg. NO or prostaglandins)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laura E Fredenburgh, MD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Weill Cornell Medical College/NewYork-Presbyterian
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
Duke Univesity Hospital
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30518685
Citation
Fredenburgh LE, Perrella MA, Barragan-Bradford D, Hess DR, Peters E, Welty-Wolf KE, Kraft BD, Harris RS, Maurer R, Nakahira K, Oromendia C, Davies JD, Higuera A, Schiffer KT, Englert JA, Dieffenbach PB, Berlin DA, Lagambina S, Bouthot M, Sullivan AI, Nuccio PF, Kone MT, Malik MJ, Porras MAP, Finkelsztein E, Winkler T, Hurwitz S, Serhan CN, Piantadosi CA, Baron RM, Thompson BT, Choi AM. A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. JCI Insight. 2018 Dec 6;3(23):e124039. doi: 10.1172/jci.insight.124039.
Results Reference
derived

Learn more about this trial

Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

We'll reach out to this number within 24 hrs